Clinical Trial

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is the first pilot phase II trial assessing the response of SBRT layered on Darolutamide (BAY1841788) on RPFS and deferring palliative second line systemic therapy in M0CRPC with oligoprogression.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-08-26; most recent amendment 2026-05-22.
Status change: Recruiting → Active, Not Recruiting 2026-05-22
Status change: Not Yet Recruiting → Recruiting 2020-10-19
Trial Details
NCT Number NCT04070209
Lead Sponsor Sir Mortimer B. Davis - Jewish General Hospital
Conditions Metastatic Prostate Cancer, Castration-resistant Prostate Cancer
Enrollment 66 participants
Start Date 2020-10-19
Primary Completion 2030-11 (estimated)
Study Completion 2030-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-27